A new study reveals that dasatinib and quercetin (D+Q) cause demyelination in mice, raising safety concerns as over 30 clinical trials test the combo for age-related diseases. A study in Nature Aging ...
Senolytics like dasatinib and quercetin are transforming dermatology from cosmetic fixes to true biological rejuvenation, with recent trials showing improved skin elasticity and potential for treating...
A comparative study reveals that dasatinib-quercetin reduces senescence and fibrosis in intervertebral disc degeneration, while navitoclax shows no benefit, highlighting DQ’s potential for affor...
Emerging senolytic treatments target cellular senescence to reduce inflammation and improve kidney function in diabetic patients, with recent clinical trials confirming safety and hinting at efficacy....
